CCR5 Delta 32 genotype is associated with outcome in type 2 diabetes mellitus

Friso L. H. Muntinghe*, Sascha Gross, Stephan J. L. Bakker, Gijs W. D. Landman, Pim van der Harst, Henk J. G. Bilo, Gerjan Navis, Mike W. Zuurman

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

23 Citaten (Scopus)

Samenvatting

Aims: To test whether the genetic variant CCR5 Delta 32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients.

Methods: We examined the effect of presence or absence of the CCR5 Delta 32 on overall and cardiovascular mortality risk in the Zwolle outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort.

Results: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5 Delta 32 deletion. CCR5 Delta 32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p = 0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p = 0.16) for cardiovascular mortality.

Conclusions: The presence of CCR5 Delta 32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Originele taal-2English
Pagina's (van-tot)140-145
Aantal pagina's6
TijdschriftDiabetes Research and Clinical Practice
Volume86
Nummer van het tijdschrift2
DOI's
StatusPublished - nov-2009

Citeer dit